Perseus Proteomics Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	135	120	100	94	71
Revenue Growth (YoY)	12.50%	20.00%	6.38%	32.39%	5.97%
Cost of Revenue	19	16	13	7	5
Gross Profit	116	104	87	87	66
Selling, General & Admin	861	336	366	290	231
Research & Development	-	594	616	494	308
Operating Expenses	861	930	982	784	539
Operating Income	-745	-826	-895	-697	-473
Interest & Investment Income	5	1	-	-	-
Currency Exchange Gain (Loss)	13	-2	16	7	9
Other Non Operating Income (Expenses)	47	-3	-1	-	-19
EBT Excluding Unusual Items	-680	-830	-880	-690	-483
Asset Writedown	-37	-72	-153	-95	-117
Other Unusual Items	-	-	-70	-	2
Pretax Income	-717	-902	-1,103	-785	-598
Income Tax Expense	1	2	1	1	1
Net Income	-718	-904	-1,104	-786	-599
Net Income to Common	-718	-904	-1,104	-786	-599
Shares Outstanding (Basic)	15	14	12	12	11
Shares Outstanding (Diluted)	15	14	12	12	11
Shares Change (YoY)	4.47%	21.05%	0.24%	6.94%	57.10%
EPS (Basic)	-48.17	-63.35	-93.65	-66.84	-54.47
EPS (Diluted)	-48.17	-63.35	-93.65	-66.84	-54.47
Free Cash Flow	-662	-794	-976	-728	-509
Free Cash Flow Per Share	-44.41	-55.65	-82.80	-61.91	-46.29
Gross Margin	85.93%	86.67%	87.00%	92.55%	92.96%
Operating Margin	-551.85%	-688.33%	-895.00%	-741.49%	-666.20%
Profit Margin	-531.85%	-753.33%	-1104.00%	-836.17%	-843.66%
Free Cash Flow Margin	-490.37%	-661.67%	-976.00%	-774.47%	-716.90%
EBITDA	-743	-824	-892	-692	-471
D&A For EBITDA	2	2	3	5	2
EBIT	-745	-826	-895	-697	-473

Source: S&P Global Market Intelligence. Standard template. Financial Sources.